Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography.

Ye H, Wang S, Hu Y, He F, Ju J, Cui H, Chen X.

Medicine (Baltimore). 2018 Aug;97(31):e11718. doi: 10.1097/MD.0000000000011718.

2.

Atorvastatin inhibits osteoclastogenesis and arrests tooth movement.

Dolci GS, Ballarini A, Gameiro GH, Onofre de Souza D, de Melo F, Fossati ACM.

Am J Orthod Dentofacial Orthop. 2018 Jun;153(6):872-882. doi: 10.1016/j.ajodo.2017.09.021.

PMID:
29853245
3.

Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report.

Dalugama C, Pathirage M, Kularatne SAM.

J Med Case Rep. 2018 May 22;12(1):143. doi: 10.1186/s13256-018-1685-0.

4.

Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin.

Matsubara A, Oda S, Akai S, Tsuneyama K, Yokoi T.

Toxicol Lett. 2018 Jul;291:184-193. doi: 10.1016/j.toxlet.2018.04.016. Epub 2018 Apr 18.

PMID:
29679711
5.

Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway.

Docrat TF, Nagiah S, Krishnan A, Naidoo DB, Chuturgoon AA.

Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.

PMID:
29630879
6.

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.

Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa AGMR, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez RRCV, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JEMR, Alexander JH, Granger CB, Lopes RD; SECURE-PCI Investigators.

JAMA. 2018 Apr 3;319(13):1331-1340. doi: 10.1001/jama.2018.2444. Erratum in: JAMA. 2018 Sep 4;320(9):938.

7.

Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life.

Ponziani MC, Karamouzis I, Mele C, Chasseur L, Zavattaro M, Caputo M, Samà MT, Busti A, Pagano L, Castello L, Marzullo P, Aimaretti G, Prodam F.

Hormones (Athens). 2017 Oct;16(4):396-404. doi: 10.14310/horm.2002.1760.

8.

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.

Mladenovska K, Grapci AD, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska NM, Nebija D, Dimovski AJ.

Pharmazie. 2017 May 1;72(5):288-295. doi: 10.1801/ph.2017.6960.

PMID:
29441875
9.

Autoimmune necrotising myopathy and HMGCR antibodies.

Karunaratne K, Amiras D, Pickering MC, Hofer M, Viegas S.

Pract Neurol. 2018 Apr;18(2):151-155. doi: 10.1136/practneurol-2017-001848. Epub 2018 Feb 8.

PMID:
29439058
10.

Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?

Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B.

Eur J Clin Pharmacol. 2018 Apr;74(4):497-504. doi: 10.1007/s00228-017-2396-y. Epub 2017 Dec 18.

PMID:
29255992
11.

Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria.

Broniarek I, Jarmuszkiewicz W.

Arch Biochem Biophys. 2018 Jan 1;637:64-72. doi: 10.1016/j.abb.2017.12.003. Epub 2017 Dec 5.

PMID:
29217137
12.

Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy.

Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM.

Biosci Rep. 2018 Jan 19;38(1). pii: BSR20171058. doi: 10.1042/BSR20171058. Print 2018 Feb 28.

13.

Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.

Herrett E, Williamson E, Beaumont D, Prowse D, Youssouf N, Brack K, Armitage J, Goldacre B, MacDonald T, Staa TV, Roberts I, Shakur-Still H, Smeeth L.

BMJ Open. 2017 Dec 1;7(12):e016604. doi: 10.1136/bmjopen-2017-016604.

14.

Atorvastatin Calcium Inhibits PDGF-ββ-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRβ-PI3K-Akt Signaling Cascade.

Chen S, Dong S, Li Z, Guo X, Zhang N, Yu B, Sun Y.

Cell Physiol Biochem. 2017;44(1):215-228. doi: 10.1159/000484648. Epub 2017 Nov 9.

15.

Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.

Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A, Das K.

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):54-59. doi: 10.1097/MEG.0000000000001006.

PMID:
29099421
16.

Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.

Park JB, Jung JH, Yoon YE, Kim HL, Lee SP, Kim HK, Kim YJ, Cho GY, Sohn DW.

Trials. 2017 Oct 27;18(1):501. doi: 10.1186/s13063-017-2229-4.

17.

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.

Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.

PMID:
29078037
18.

Does posttreatment thymoquinone reverse high-dose atorvastatin-induced hepatic oxidative injury in rats?

Hassan SS, Razzaque A, Ahmad Z, Pazdernik V, Amin SN.

Can J Physiol Pharmacol. 2018 Jan;96(1):51-59. doi: 10.1139/cjpp-2017-0599. Epub 2017 Oct 2.

PMID:
28968507
19.

Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle.

Simakova MN, Bisen S, Dopico AM, Bukiya AN.

Biochem Pharmacol. 2017 Dec 1;145:81-93. doi: 10.1016/j.bcp.2017.08.022. Epub 2017 Sep 1.

PMID:
28865873
20.

Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study.

Chen Y, Li D, Jing J, Yan H, Liu J, Shen Z, James S, Varenhorst C.

Clin Ther. 2017 Sep;39(9):1827-1839.e1. doi: 10.1016/j.clinthera.2017.07.042. Epub 2017 Aug 12.

PMID:
28807393

Supplemental Content

Loading ...
Support Center